Document is current

Article History

Received: 19 December 2023

Accepted: 24 July 2024

First Online: 5 August 2024

Competing interests

: A.L., T.D., Q.Y., M.G.R., and M.M.S. are employees and own restricted stock units of Tempus AI, Inc. A.S. owns restricted stock units of Tempus AI, Inc. A.L. and W.Y.G. hold patents related to the HLA LOH test (A.L. US20230154563A1; W.Y.G MX2020007543A). J.S.W., W.Y.G., E.W.N., and A.M. are employees of A2 Biotherapeutics and hold A2 Biotherapeutics stock options. D.G.M. holds stock options in A2 Biotherapeutics and Navan Technologies, and research funding from Kite Pharma, Juno Therapeutics, Celgene, Legend Biotech, and Bristol-Myers Squibb. E.B.G. holds grants from ABL-Bio; AstraZeneca; Bristol Myers Squibb; Dynavax Technologies; Eli Lilly; EMD Serono; Genentech; Iovance Biotherapeutics; Merck; Mirati Therapeutics; Neon; and Novartis, and is a consultant or advisor for: Abbvie; ABL-Bio; AstraZeneca, Boehringer-Ingelheim; Bristol Myers Squibb; Dracen Pharmaceuticals; EMD Serono; Eisai; Eli Lilly; Gilead; GlaxoSmithKline; Merck; Natera; Novartis; Personalis; Regeneron; Sanofi; Shionogi; and Xilio. Joel R. Hecht owns stock options of Actym, Triumvirate and Rafael. His research is funded by A2 Biotherapeutics, Revolution Medicine, Regeneron, Seagen, Pfizer, Janssen, Gilead, Exelixis, Affin-T, Neogene, Lyell, Cardiff, IGM, NGM, Tizona, Camurus, Crinetics, Gritstone, Mirati, Agenus. Advisor for BMS, Astellas, Novartis, BeiGene. K.K. receives travel support from A2 Biotherapeutics. The remaining authors declare no competing interests.